MDxHealth (MDxHealth) LT-Debt-to-Total-Asset : 0.29 (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is MDxHealth LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MDxHealth's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.29.

MDxHealth's long-term debt to total assets ratio declined from Sep. 2022 (0.30) to Sep. 2023 (0.29). It may suggest that MDxHealth is progressively becoming less dependent on debt to grow their business.

MDxHealth LT-Debt-to-Total-Asset Historical Data

The historical data trend for MDxHealth's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MDxHealth LT-Debt-to-Total-Asset Chart

MDxHealth Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.24

0.39

0.14

0.32

MDxHealth Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.30	0.32	0.25	0.27	0.29

MDxHealth LT-Debt-to-Total-Asset Calculation

MDxHealth's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	38.005	/	119.135
	=	0.32

MDxHealth's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	38.696	/	135.733
	=	0.29

MDxHealth (NAS:MDXH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MDxHealth LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of MDxHealth's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MDxHealth (MDxHealth) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

BIOQ PSNL VNRX PRE ENZ PRPH ACRS BNR DRIO AWH TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

N/A

Address

Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040

Website

https://www.mdxhealth.com

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.